FAP-targeted PET/NIR in Lung Malignant Tumors
Recruiting
Observational Study
Non-Small Cell Lung Cancer
PET/CT
Neoadjuvant Therapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Peking University People's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor les…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age between 18 and 70 years old;
* Have complete clinical and imaging data;
* Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
* Able to retain sufficient tumor tissue for testing and research;
* Sign informed consent.
Exclusion Criteria:
* Previously c…
Contacts